Research programme: anti-CD11 antibody fragment - InNexusAlternative Names: IXSCD 11a
Latest Information Update: 16 Jul 2016
At a glance
- Originator InNexus Biotechnology
- Class Antibodies
- Mechanism of Action CD11a antigen antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psoriasis in USA (Topical, Patch)
- 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in USA (Topical, Lotion)
- 06 Jan 2010 Early research in Psoriasis in USA (Topical)